Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPI-145 in Mild Asthma Subjects Undergoing Allergen Challenge
2012-001729-28Phase 2Completed
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of duvelisib in asthma (2 arms), sponsored by Infinity Pharmaceuticals, Inc. Primary endpoint: Maximal decrease in FEV1 following allergen challenge (EAR and LAR). Started May 2012; status: completed.
02
Drugs
duvelisib
03
Conditions
asthma
Beyond the preview
Go deeper on 2012-001729-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001729-28.